Pi-Cardia’s ShortCut™ Becomes First Leaflet Modification Technology to Receive CMS NTAP for Valve-in-Valve TAVR
Pi-Cardia Inc., a global leader in the development of leaflet modification solutions for treating heart valves, today announced that the Centers for Medicare & Medicaid Services (CMS) has approved a New Technology Add-On Payment (NTAP) for the ShortCut™ device, effective October 1, 2025. The NTAP designation recognizes ShortCut™ as a breakthrough technology that addresses a critical unmet need in valve-in-valve transcatheter aortic valve replacement (TAVR) by enabling treatment for patients at risk of coronary obstruction.
Pi-Cardia Reports First Commercial Cases with ShortCut™
Pi-Cardia Inc., a global leader in the development of leaflet modification solutions for treating heart valves, announced today the first commercial procedures with ShortCut™ - the world's first dedicated leaflet modification device, enabling valve-in-valve (ViV) Transcatheter Aortic Valve Replacement (TAVR) procedures in patients at risk of coronary obstruction. The news follows the ShortCut™ De Novo market clearance granted by the United States Food and Drug Administration (FDA) in September 2024.
